Artiva Biotherapeutics, Inc. (ARTV): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Artiva Biotherapeutics, Inc. (ARTV) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Elizabeth Hougen as a Class III Director On November 11, 2026, Elizabeth Hougen notified the Company of her

Event · Exec change
Person
Elizabeth Hougen
Title
Class III Director
Action
resigned
Effective
effective immediately

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 17, 2026, 9:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$ARTV
Neutral
medium confidence
Mentioned
$ARTV
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ARTVNeutralLow
01

Why it matters

The disclosure confirms a Class III director resignation effective immediately, with no stated disagreement on company operations, policies, or practices.

02

Market read

This is governance-related news with limited immediate trading implications absent additional context such as replacement directors, committee changes, or operational disputes.

03

What to watch

Traders may be over-weighting governance optics; without details on committee roles, replacement timing, or any disagreement, the fundamental impact is likely small.

Relevance 6/10Novelty 4/10Timing: filed Nov 17, 2026, after-hours/late session disclosure

Background

The company filed an SEC Form 8-K under Item 5.02 covering director/officer changes and compensatory arrangements.

Company-level read

Ticker impact

$ARTVNeutralMedium confidence
Context

Artiva Biotherapeutics disclosed Elizabeth Hougen’s immediate resignation as a Class III director in an Item 5.02 8-K.

Expected impact

Likely limited near-term impact, with any move driven by governance sentiment rather than fundamentals.

Evidence & confidence

The filing is a director resignation notice without stated disagreements, disputes, or business-impact details; such events typically have modest, sentiment-driven effects unless tied to broader problems.

Market effects

Minimal sector read-through; this is company-specific governance news with no stated biotech pipeline or regulatory linkage.

No clear regional spillover expected.

No global market relevance indicated.

Counterpoint

The resignation could be routine or planned, with no negative signal if the company simultaneously appoints a replacement (not included in the provided text).

Key entities

  • Artiva Biotherapeutics, Inc.

    US-listed biotech issuer filing the 8-K.

  • Elizabeth Hougen

    Class III director who resigned effective immediately on Nov 11, 2026.

  • Fred Aslan

    CEO signing the filing.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.